Probi names Ole Søgaard Andersen as Interim CEO

Probi AB (publ) ("Probi"), today announced the appointment of Ole Søgaard Andersen as interim Chief Executive Officer, effective immediately. Ole Søgaard Andersen replaces CEO Peter Nählstedt.

Ole Søgaard Andersen is an accomplished international business leader with over 30 years’ experience in ingredients companies. He formerly held positions as President, Systems Division and Global Vice President Sales, Marketing & Application for Nutrition and Health, at DuPont. He also served on Danisco’s Board of Executives.

Probi will retain an executive search firm to recruit a new CEO to further enhance the Company’s strategies and to take Probi to its next phase of development and growth.

"We thank Peter Nählstedt for his achievements in developing Probi into a leading global probiotics company and for his dedicated service to the company. Probi is already in a good position to carry on with its growth strategy. I am convinced that Ole Søgaard Andersen will fully utilise the growth opportunities in the market, until a new permanent CEO has been appointed", said Jean-Yves Parisot, Chairman of the Board.

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 14 March 2018 at 15.50pm CET.

Jean-Yves Parisot, Chairman of the Board, Probi, tel +33 670 48 0684, e-mail:
Niklas Brandt, CIO & Investor Relations, Probi, tel +46 46 286 89 26, e-mail:

Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at 


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on



Documents & Links